Idiopathic Parkinson's Disease

PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease

Comparison of [18F] FDOPA PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease: Pilot Study

david groshar

Prof. David Groshar

Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, or at least one gadolinium enhancing lesion on a MRI within 3 months of enrollment.
The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28.

Subjects meeting the definition for SPMS by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year
The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28.

Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26
The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28.

This group will serve as non disease population.
The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28.

Multiple Sclerosis

Alzheimer's Disease

[F-18]PBR06

Partners MS Center, 60 Fenwood Road

Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease

Tarun Singhal

Associate Neurologist

Brigham and Women's Hospital

18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue

Hepatocellular Carcinoma

18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.

18F-FluoroethylCholine PET

Department of liver surgery; Peking Union Medical College Hospital

18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma

Diagnostic Accuracy of 18F-FluoroethylCholine Positron Emission Tomography for Hepatocellular Carcinoma

The studied population will be consisted of the patients with a suspicion of HCC treated in our hospital from October 2014 to October 2015. Patients following the Inclusion criteria and Exclusion criteria will undergo 18F-FECH and 18F-FDG PET examinations before clinical treatments. The maximum standard uptake value (SUVmax) of liver lesions and the mean SUV of the non-affected liver (SUVmean) will be measured. SUVratio will be calculated as SUVmax/ SUVmean.

Patients' lifespan and survival condition will be measured. The follow-up of the patients will end in April 2017. Tumor size, intensity of arterial enhancement on dynamic imaging of the primary lesion, and extent of disease after patients' treatments will be measured on CT and/or MRI.

A receiver operating characteristic (ROC) curve will be performed to assess the cutoff for the SUV. Sensitivity and specificity are based on McNemar's test. The results of 18F-FECH PET and pathological diagnosis for matching are compared by Kappa test. Pearson's chi square and Fisher's exact correlation tests are used for categorical data analyses. Survival analysis will be performed and survival curves were plotted by Kaplan-Meier method. Log-rank test is used for the comparison between the two survival curves. One-way ANOVA with Tukey's test is used to evaluate the gene expressions. Date analysis will help us to evaluate the sensitivity, specificity and accuracy of 18F-FECH PET in diagnosis of HCC, to assess the accuracy of 18F-FECH PET in diagnosis of HCC at the early stage (diameter ≤ 3cm), and to explore the difference of 18F-FECH PET imaging findings between early or late HCC lesions in order to guide the clinical application in the future.

fluorine/atrofia

PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease

Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease

18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo